tiprankstipranks
Trending News
More News >

Prothena downgraded to Underperform at BofA after birtamimab fails in clinic

As previously reported, BofA downgraded Prothena (PRTA) to Underperform from Neutral with a price target of $4, down from $22, after lead drug birtamimab failed its Phase 3 trial to treat Mayo Stage IV AL Amyloidosis. Prothena continues to develop PRX012, a monoclonal antibody for Alzheimer’s disease, but it is still in early development and the firm assumes a conservative stance on this opportunity as currently approved therapies have not met expectations, the analyst tells investors.

Confident Investing Starts Here:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.

Report an Issue